Serum Based miRNA as a Diagnostic Biomarker for Multiple Sclerosis: a Systematic Review and Meta-Analysis
- PMID: 33660581
- DOI: 10.1080/08820139.2021.1887888
Serum Based miRNA as a Diagnostic Biomarker for Multiple Sclerosis: a Systematic Review and Meta-Analysis
Abstract
This systematic review and meta-analysis aimed to identify deferentially expressed serum miRNAs in multiple sclerosis patients and to evaluate their diagnostic value in multiple sclerosis diagnosis. Studies were identified on PubMed, Google scholar and Saudi digital library up to 30 September 2019. Articles that examined miRNA expression level in MS patients compared to healthy control group were included in the review and the data were extracted by three independent author. The comprehensive Meta-Analysis version 3 software was used for meta-analysis and heterogeneity of studies was identified according to I2 value. Our literatures search identified 9 eligible articles concerning the serum miRNA as a diagnostic biomarker for multiple sclerosis in comparison to healthy control group. 19 serum miRNAs differentially expressed in MS patients were identified (8 downregulated, 11 upregulated and 1 with discordant result). In publications that provided information on specific miRNA diagnostic value, the pooled AUC was 72% (95% CI 0.65-0.78, p-value 0.00) for the overall multiple sclerosis patients and primary progressive MS (PPMS) (95% CI 0.66-0.78 p-value 0.00). A miRNA panel of four miRNAs showed high sensitivity (73%) and specificity (68%) in distinguishing multiple sclerosis from control groups. When using single miRNA (miR-145), the sensitivity increased to 79% and the specificity to 87%. The available data from the literature and this meta-analysis suggests the potential use of serum miRNA as biomarkers for early diagnosis of MS with high sensitivity and specificity in distinguishing multiple sclerosis subtypes from healthy controls.Abbreviation: MS: Multiple sclerosis; IDD: inflammatory demyelinating diseases; RRMS: relapsing-remitting Multiple sclerosis; PPMS: primary progressive Multiple sclerosis; SPMS: secondary progressive Multiple sclerosis; NMO: Neuromyelitis optica; miRNA: microRNA; ECmiRNA: extracellular microRNA; AUC: Area Under the Curve; ROC: Receiver Operator Characteristic.
Keywords: Mirna; biomarker; multiple sclerosis.
Similar articles
-
Analysis of potential microRNA biomarkers for multiple sclerosis.Exp Mol Pathol. 2024 Jun;137:104903. doi: 10.1016/j.yexmp.2024.104903. Epub 2024 May 20. Exp Mol Pathol. 2024. PMID: 38772208
-
Erythrocyte microRNA sequencing reveals differential expression in relapsing-remitting multiple sclerosis.BMC Med Genomics. 2018 May 21;11(1):48. doi: 10.1186/s12920-018-0365-7. BMC Med Genomics. 2018. PMID: 29783973 Free PMC article.
-
MiRNA 106a-5p in cerebrospinal fluid as signature of early relapsing remitting multiple sclerosis: a cross sectional study.Front Immunol. 2023 Aug 30;14:1226130. doi: 10.3389/fimmu.2023.1226130. eCollection 2023. Front Immunol. 2023. PMID: 37711630 Free PMC article.
-
A Meta-Analytic Review of the Value of miRNA for Multiple Sclerosis Diagnosis.Front Neurol. 2020 Feb 25;11:132. doi: 10.3389/fneur.2020.00132. eCollection 2020. Front Neurol. 2020. PMID: 32158427 Free PMC article.
-
Role of Chitinase 3-like 1 as a Biomarker in Multiple Sclerosis: A Systematic Review and Meta-analysis.Neurol Neuroimmunol Neuroinflamm. 2022 May 9;9(4):e1164. doi: 10.1212/NXI.0000000000001164. Print 2022 Jul. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 35534236 Free PMC article.
Cited by
-
Overview of miR-106a Regulatory Roles: from Cancer to Aging.Bioengineering (Basel). 2023 Jul 27;10(8):892. doi: 10.3390/bioengineering10080892. Bioengineering (Basel). 2023. PMID: 37627777 Free PMC article. Review.
-
Exploring the theranostic potentials of miRNA and epigenetic networks in autoimmune diseases: A comprehensive review.Immun Inflamm Dis. 2023 Dec;11(12):e1121. doi: 10.1002/iid3.1121. Immun Inflamm Dis. 2023. PMID: 38156400 Free PMC article. Review.
-
Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations.Int J Mol Sci. 2022 Mar 21;23(6):3383. doi: 10.3390/ijms23063383. Int J Mol Sci. 2022. PMID: 35328802 Free PMC article. Review.
-
Non-coding RNAs: emerging biomarkers and therapeutic targets in cancer and inflammatory diseases.Front Oncol. 2025 Mar 10;15:1534862. doi: 10.3389/fonc.2025.1534862. eCollection 2025. Front Oncol. 2025. PMID: 40129920 Free PMC article. Review.
-
Molecular Biomarkers and Their Implications for the Early Diagnosis of Selected Neurodegenerative Diseases.Int J Mol Sci. 2022 Apr 21;23(9):4610. doi: 10.3390/ijms23094610. Int J Mol Sci. 2022. PMID: 35563001 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical